Fosdevirine

Drug Profile

Fosdevirine

Alternative Names: '761; 2248761 - ViiV Healthcare; GSK2248761; GSK2248761A; IDX-12899; IDX-899

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Idenix Pharmaceuticals
  • Developer GlaxoSmithKline; ViiV Healthcare
  • Class Amides; Antivirals; Indoles; Nitriles; Phosphinic acids; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 15 Mar 2012 Fosdevirine is no longer licensed to ViiV Healthcare
  • 05 May 2011 GlaxoSmithKline terminates a phase I drug-interaction trial in the USA (NCT01195974)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top